Pharmacological characterization of a novel Nav1.7 channel inhibitor for antinociception
编号:73 访问权限:仅限参会人 更新:2021-08-03 19:17:25 浏览:994次 张贴报告

报告开始:2021年08月07日 08:40(Asia/Shanghai)

报告时间:20min

所在会场:[S2] Poster session [Po] Poster session

视频 无权播放 演示文件

提示:该报告下的文件权限为仅限参会人,您尚未登录,暂时无法查看。

摘要
Pain treatment presents an unmet medical need. The voltage-gated sodium channel Nav1.7 is abundantly expressed in peripheral nociceptive neurons. Genetic studies demonstrate that the gain-of-function mutations of Nav1.7 can cause hyperalgesia, while its loss-of-function mutations can cause congenital insensitivity to pain (CIP). These observations suggest that pharmacological inhibition of Nav1.7 may hold therapeutic potential for chronic pain. Based on a drug candidate ralfinamide as Nav1.7 inhibitor in phase III clinical trial, a novel small molecule QLS-127 was synthesized and identified. Here, we report that QLS-127 inhibits Nav1.7 channel and exhibits antinociceptive activity. Whole-cell patch-clamp recordings of HEK293 cells stably expressing Nav1.7 reveal that QLS-127 inhibits the peak current of Nav1.7 in a dose-dependent manner (IC50 = 2.9 ± 0.8 uM), and its potency was about 12-fold batter than that of ralfinamide (IC50 = 35.2 ± 2.8 uM). In vivo test shows that QLS-127 (5, 10, 20 mg/kg, i.p.) dose-dependently alleviated spared nerve injury (SNI)-induced neuropathic pain in mice. In addition, QLS-127 (20 mg/kg, i.p.) had no obvious effect on the locomotor activity. These results suggest that QLS-127-mediated antinociceptive activity is likely resulted from the inhibition of Nav channels, but not from the sedation effect. Furthermore, the Nav1.7 channel inactivation dynamics and selectivity evaluation of QLS-127 are in progress.

 
关键词
Nav1.7,inhibitor,antinociception,QLS-127,therapeutic target
报告人
董黎颖
青岛大学

稿件作者
董黎颖 青岛大学
刘雅妮 青岛大学
王克威 青岛大学药学院
发表评论
验证码 看不清楚,更换一张
全部评论
重要日期
  • 会议日期

    08月06日

    2021

    08月09日

    2021

  • 08月09日 2021

    注册截止日期

主办单位
中国神经科学学会离子通道与受体分会
承办单位
河北工业大学
历届会议
移动端
在手机上打开
小程序
打开微信小程序
客服
扫码或点此咨询